[1] | Roché, H., Fumoleau, P., Spielmann, M., Canon, J. L., Delozier, T., Serin, D., ... & Asselain, B. (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology, 24(36), 5664-5671. |
|
[2] | García-Quintana, A., Martín-Lorenzo, P., Suárez de Lezo, J., Díaz-Escofet, M., Llorens, R., & Medina, A. (2005). Infected left atrial myxoma. Revista Española de Cardiología (English Edition), 58(11), 1358-1360. |
|
[3] | Walpot, J., Shivalkar, B., Rodrigus, I., Pasteuning, W. H., & Hokken, R. (2010). Atrial myxomas grow faster than we think. Echocardiography, 27(10), E128-E131. |
|
[4] | Roudaut, R., Gosse, P., & Dallocchio, M.. (1987). Rapid growth of a left atrial myxoma shown by echocardiography. British heart journal, 58(4), 413-416. |
|
[5] | Malekzadeh, S., & Roberts, W. C. (1989). Growth rate of left atrial myxoma. The American journal of cardiology, 64(16), 1075-1076. |
|
[6] | Olson, R. D., & Mushlin, P. S. (1990). Doxorubicin cardiotoxicity: analysis of revailing hypotheses. The FASEB journal, 4(13), 3076-3086. |
|
[7] | Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., .. & Hall, P. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine, 368(11), 987-998. |
|
[8] | Sengupta, P. P., Northfelt, D. W., Gentile, F., Zamorano, J. L., & Khandheria, B. K. (2008, February). Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. In Mayo Clinic Proceedings (Vol. 83, No. 2, pp. 197-203). Elsevier. |
|
[9] | Senkus-Konefka, E., & Jassem, J. (2007). Cardiovascular effects of breast cancer radiotherapy. Cancer treatment reviews, 33(6), 578-593. |
|